|
OMNICOMM SYSTEMS, INC. AND LOGOS TECHNOLOGIES PARTNER TO PROVIDE SUPERIOR ELECTRONIC
DATA CAPTURE (EDC) SOLUTIONS FOR PHASE I – IV CLINICAL TRIALS
Leader in integrated EDC solutions and time tested experts in early Phase EDC join
forces and integrate their systems to expand the use of EDC in Phase I-IV studies
FT. LAUDERDALE, FL – April 4, 2008 – /MarketWire/ - OmniComm Systems, Inc. (OTC:
OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical
trials, today announced that OmniComm will partner with Logos Technologies and create
an integrated solution with ALPHADAS ®, the premier electronic data capture
solution designed specifically for Phase I clinical trials. The combined technologies
will be available for use by customers using the TrialMaster™, First in Functionality™,
EDC solution. The collaboration will allow customers that are conducting clinical
research in Phase I to take advantage of a clinical study management and fully mobile
electronic data capture system to capture data directly from the patient’s bedside.
For those clients running Phase I-IV clinical studies, the combination will unify
the capture, reporting, exporting and archival of clinical data into a common, cost-effective,
web-based, user-interface. The final warehouse for data may reside in SQL, Oracle
Clinical® database tables or in SAS®.
“One of the fastest growing segments for EDC adoption in clinical trials is in the
Phase I area. The report from Health Industry Insights, U.S. Electronic Data Capture
2006-2011- Spending Forecast and Analysis, predicts that growth is expected to more
than double in the US alone over the next two to three years,” said Stephen Johnson,
Chief Operating Officer for OmniComm. “The interface between Logos Technologies
and OmniComm will offer a superior and dynamic EDC solution for customers that are
focused on Phase I clinical trials and deliver an excellent addition to our suite
of targeted, integrated solutions for our existing customers. The integration of
OmniComm’s TrialMaster and Logos Technologies ALPHADAS extends the capabilities
for data collected from ALPHADAS to be combined with clinical data imported from
other outside sources. This combined data may then be exported, archived and made
available to our clients in various reports and reporting formats. It also offers
our clients running Phase I-IV clinical studies a common, cost-effective, web-based,
interface to use across their enterprise.”
“Phase I clinical studies are unique in the way that they are conducted and they
need versatile solutions that are focused on the challenges that are inherent to
the Phase I setting. ALPHADAS first launched over 10 years ago has assisted clients
to run hundreds of studies quicker and more efficiently,” said Giles Wilson, Business
and Operations Director for Logos. “The need for real time data capture in Phase
I studies continues to increase, drug development companies are looking for solutions
that will produce faster access to data and earlier go / no go decisions while reducing
costs throughout the whole Phase I process. The partnership between Logos Technologies
and OmniComm now offers companies a way to truly benefit from EDC from the very
onset of their trial through to database lock.”
About Logos Technologies
Logos Technologies, www.logostechnologies.com,
is a leading provider of world-class integrated clinical trial solutions to the
world’s pharmaceutical, biotechnology and clinical research organizations. The ALPHADAS
Suite is a clinical study management and fully mobile Phase I proactive EDC system
that has been designed for real time eSource data collection. The system provides
time based data entry at the bedside, collection and integration of laboratory data,
images and scans and Bar-coded labeling to track samples from draw to dispatch.
Logos Technologies’ established and proven product ALPHADAS sets the standard in
collecting Phase I clinical trial data. ALPHADAS is fully compliant with industry
standards and guidelines including FDA 21 CFR Part 11.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions
to pharmaceutical, biotechnology, research and medical device organizations that
conduct life changing clinical trial research. OmniComm’s growing base of satisfied
customers is a direct result of the company’s commitment to deliver products and
services that ensure ease of use, faster study build, ease of integration and better
performance. OmniComm’s client intuitive pricing model allows companies that range
from small to mid-size to large scale institutions to safely and efficiently capitalize
on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters
in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California,
Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation, future
revenues and earnings, plans and objectives for the future operations, future agreements,
future economic performance, operations and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. OmniComm intends that such forward-looking statements be subject to
the Safe Harbors created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm’s operations, markets and profitability,
actual results could differ materially and adversely from the expected results.
CONTACT:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283
lkelley@omnicomm.com
CONTACT:
Angela King
Logos Technologies
+44(0)8707 478900
angela.king@logostechnologies.com
Back
|
